Oncternal Therapeutics – Strategy, SWOT and Corporate Finance Report
- Pages: 40
- Published: October 2019
- Report Code: MLPH29790FSA
Oncternal Therapeutics – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company
Key Highlights
Oncternal Therapeutics (Oncternal) is a biopharmaceutical company that discovers, develops and commercializes novel targeted hormonal therapies. It develops small molecules that targets hormone pathways for the treatment of various cancers including breast and prostate cancer; and other serious medical conditions. The company has license agreement with the university of tennessee research foundation (UTRF) under which it is developing selective androgen receptor degrader, (SARD) technology. It develops compounds based on SARD technology which can antagonize or degrade multiple forms of androgen receptor and potentially inhibiting the tumor growth in patients resistant to progressive castration prostate cancer or those patients with resistant to current androgen therapies. Oncternal is headquartered in Memphis, Tennessee, the US.
Scope
Detailed information on Oncternal Therapeutics required for business and competitor intelligence needs
A study of the major internal and external factors affecting Oncternal Therapeutics in the form of a SWOT analysis
An in-depth view of the business model of Oncternal Therapeutics including a breakdown and examination of key business segments
News about Oncternal Therapeutics, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
Gain understanding of Oncternal Therapeutics and the factors that influence its strategies.Track strategic initiatives of the company and latest corporate news and actions.
Assess Oncternal Therapeutics as a prospective partner, vendor or supplier.
Support sales activities by understanding your customers' businesses better.
Stay up to date on Oncternal Therapeuticss business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
GlaxoSmithKline Plc
Gilead Sciences Inc
CellCentric Ltd
Astellas Pharma Inc
Cogentix Medical Inc
Zenith Epigenetics Ltd
Pfizer Inc
Johnson & Johnson
Incyte Corp
Carmot Therapeutics Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.